Skip to main content

Table 5 Health impact of alternative scale-up scenarios in the GAVI-eligible countries

From: Health and economic impact of rotavirus vaccination in GAVI-eligible countries

No Scale-up scenarios No. of children vaccinated
(in million)
No. of outpatient visits averted
(r = 0%) (in million)
No. of hospitalization averted
(r = 0%) (in million)
No. of deaths averted
(r = 0%) (in million)
YL saved
(r = 3%) (in million)
DALYs averted
(r = 3%) (in million)
1 Base-case rollout scenario (Table 2)       
  Vaccine efficacy based on the SAGE approach       
  Vaccine immunity waning (14% annually) 281.8 40.7 4.5 0.9 20.3 20.4
2 Base-case rollout scenario (Table 2)       
  Vaccine efficacy based on the SAGE approach       
  No vaccine immunity waning 281.8 44.1 4.9 1.0 22.0 22.1
3 Base-case rollout scenario (Table 2)       
  Vaccine efficacy adjusted for serotype distribution       
  Vaccine immunity waning (14% annually) 281.8 47.8 5.6 1.2 25.3 25.4
4a Base-case rollout scenario (Table 2)       
  Vaccine efficacy adjusted for serotype distribution       
  No vaccine immunity waning 281.8 51.7 6.0 1.3 27.3 27.4
5 (Modified) Wolfson et al. scenario [37]       
  Vaccine efficacy based on the SAGE approach       
  No vaccine immunity waning 410.5 64.2 7.7 1.6 35.6 35.7
6 (Modified) Wolfson et al. scenario [37]       
  Vaccine efficacy adjusted for serotype distribution       
  No vaccine immunity waning 410.5 81.4 10.4 2.2 48.1 48.3
7 A flat coverage of 70%       
  Vaccine efficacy based on the SAGE approach       
  No vaccine immunity waning 537.0 85.9 10.1 2.1 48.9 49.1
8 A flat coverage of 70%       
  Vaccine efficacy adjusted for serotype distribution       
  No vaccine immunity waning 537.0 106.6 13.3 2.8 64.5 64.7
  1. r = discount rate; YL = years of life; DALYs = disability-adjusted life-years; I$ = international dollars; SAGE = Strategic Advisory Group of Experts on Immunization.
  2. a Base-case analysis.